Although there are currently no trials of therapy targeting CD40L or ICOS in SSc patients, a promising study in patients with rheumatoid arthritis using of an anti-CD40 antagonist Mab leads to a decrease in activated B-cells and autoantibody production [62]. This evidence concerns the gene CD40 and rheumatoid arthritis.